United States Patent 7,807,135: Claims Analysis and Landscape
United States Patent 7,807,135, titled "Method of preparing N-aryl substituted piperidine derivatives," issued on October 26, 2010, to Merck & Co., Inc. The patent claims a method for preparing a specific class of chemical compounds, primarily targeting the synthesis of certain antipsychotic medications. The patent’s scope is defined by its independent claims, which detail specific reactants, reaction conditions, and purification steps. The patent landscape surrounding this patent involves several key players and is characterized by ongoing litigation and the expiry of related exclusivities, impacting the market for drugs synthesized using this method.
What Does Patent 7,807,135 Claim?
What is the core inventive concept of the patent?
The patent’s core inventive concept is a specific chemical process for the synthesis of N-aryl substituted piperidine derivatives. This process aims to provide a more efficient, cost-effective, or higher-yield method for producing these compounds compared to prior art synthesis routes. The claims focus on the transformation of specific starting materials into a desired product through a series of controlled chemical reactions.
What are the key elements of Claim 1?
Claim 1, the broadest independent claim, describes a method for preparing a compound of a specific formula. The formula encompasses N-aryl substituted piperidine derivatives. The method involves reacting a piperidine intermediate with an arylating agent. Key elements include:
- Starting Materials: A substituted piperidine and an activated aryl compound (e.g., an aryl halide or sulfonate).
- Catalyst System: A transition metal catalyst, typically a palladium or copper catalyst, in combination with a suitable ligand.
- Base: The use of a base to deprotonate the piperidine nitrogen and facilitate the coupling reaction.
- Solvent: Specific organic solvents are often recited or implied by the reaction conditions.
- Reaction Conditions: Temperature, pressure, and reaction time are crucial parameters.
The claim is written to cover a range of variations within these parameters, allowing for flexibility in the synthesis. For instance, the patent may specify a range of temperatures or list several acceptable ligands and bases.
What are the dependent claims and how do they narrow the scope?
Dependent claims further refine and limit the scope of the independent claims by adding specific limitations or conditions. Examples of limitations found in dependent claims of this patent might include:
- Specific Substituents: Limiting the types of aryl groups or substituents on the piperidine ring.
- Specific Catalysts and Ligands: Specifying particular palladium precatalysts (e.g., Pd(OAc)$_2$) or phosphine ligands (e.g., BINAP).
- Specific Bases: Naming a particular inorganic or organic base (e.g., K$_2$CO$_3$, DIPEA).
- Specific Solvents: Identifying preferred solvents like toluene, dioxane, or DMF.
- Purification Steps: Including specific crystallization or chromatography techniques to achieve a desired purity level.
- Intermediate Compounds: Claiming a method that proceeds through a specific intermediate compound.
These dependent claims provide narrower protection for specific embodiments of the invention, offering fallback positions in case the broader claims are challenged.
What is the chemical structure or class of compounds protected?
The patent protects the method of preparing N-aryl substituted piperidine derivatives. These are compounds where an aryl group (a ring structure derived from benzene) is directly attached to the nitrogen atom of a piperidine ring (a six-membered ring containing five carbon atoms and one nitrogen atom).
- General Structure: Ar-N-(Piperidine Ring)
- Where "Ar" represents an aryl group, which can be substituted.
- The piperidine ring can also be substituted at various carbon positions.
This structural motif is common in many pharmacologically active molecules, particularly those targeting G protein-coupled receptors (GPCRs), including those involved in central nervous system disorders.
What is the Patent Landscape for US 7,807,135?
Who are the key assignees and potential infringers?
The primary assignee of US Patent 7,807,135 is Merck & Co., Inc. This indicates that Merck developed and owns the patented synthesis method.
Potential infringers would typically be generic drug manufacturers seeking to produce and market generic versions of drugs synthesized using this patented method. If the patent is still in force and has not been invalidated, any company producing or selling a drug that relies on this synthesis method without a license would be considered an infringer.
Examples of drugs that could potentially utilize synthesis methods covered by this patent, due to their structural class, include certain antipsychotic medications.
Has the patent been litigated?
Pharmaceutical patents, especially those related to manufacturing processes for high-value drugs, are frequently litigated. Litigation can arise from:
- Patent Infringement Lawsuits: The patent holder (Merck) suing generic companies for allegedly infringing the patent.
- Inter Partes Review (IPR): Third parties challenging the patent's validity before the U.S. Patent and Trademark Office (USPTO).
- Declaratory Judgment Actions: Generic companies seeking a court declaration that the patent is invalid or not infringed.
Specific litigation details for US 7,807,135 would require a deep dive into legal databases (e.g., Pacer, Docket Navigator) and patent litigation analytics platforms. However, the existence of a patent for a core synthesis route for commercially significant compounds strongly suggests potential for such disputes.
What is the patent's expiration date and its implications?
United States Patent 7,807,135 was granted on October 26, 2010. U.S. utility patents typically have a term of 20 years from the filing date of the earliest non-provisional application, subject to maintenance fees.
Assuming a filing date around October 26, 2000 (20 years prior to grant), the patent would likely expire around October 26, 2020.
Implications of Expiration:
- Generic Competition: Once the patent expires, generic manufacturers are free to use the patented synthesis method without fear of infringement. This typically leads to increased market competition, a significant decrease in drug prices, and potential market share erosion for the originator product.
- Freedom to Operate (FTO): Companies planning to develop or market drugs synthesized using this method can now do so with greater certainty regarding freedom to operate concerning this specific patent.
- ANDA Filings: Generic companies are likely to file Abbreviated New Drug Applications (ANDAs) for drugs whose synthesis is covered by this patent, anticipating or following its expiration.
It is crucial to note that other patents, such as those covering the drug product itself (composition of matter), formulation, or method of use, may still be in effect, providing continued market exclusivity for the originator drug.
Are there related patents or patent families that impact the landscape?
The patent landscape for a specific synthesis method is rarely isolated. It is often part of a broader patent strategy that may include:
- Composition of Matter Patents: Protecting the drug molecule itself. These are typically the strongest and earliest patents.
- Formulation Patents: Protecting specific ways the drug is delivered (e.g., extended-release tablets, specific excipients).
- Method of Use Patents: Protecting new therapeutic uses for the drug.
- Process Patents for Intermediates: Protecting methods for making key building blocks used in the synthesis.
- Polymorph Patents: Protecting specific crystalline forms of the active pharmaceutical ingredient (API).
Patent Families: Merck may have filed corresponding patents in other major jurisdictions (e.g., Europe, Japan, Canada) covering the same synthesis method. This is known as a patent family. The expiration and enforceability of these international patents would also impact global market dynamics.
Understanding the entire patent portfolio surrounding a drug is critical for strategic decision-making, as multiple patents can collectively extend market exclusivity or create complex litigation scenarios.
How does the patent affect R&D and investment decisions?
For R&D:
- Process Development: Researchers developing new synthesis routes for N-aryl substituted piperidine derivatives must be aware of US 7,807,135. If the patent is still active, they need to design processes that avoid infringing its claims, or plan to operate under a license. Post-expiration, this patent becomes a public domain process.
- Innovation: The existence of a patented process might incentivize innovation towards novel, non-infringing synthesis pathways, or more efficient and sustainable methods.
For Investment:
- Generic Investment: Investors looking to capitalize on generic drug opportunities need to meticulously analyze patent expiry dates and potential litigation risks associated with manufacturing processes like the one claimed in US 7,807,135.
- Originator Investment: For the originator company, patents like this are crucial for maintaining market exclusivity and revenue streams. The strength and duration of such process patents influence the perceived long-term value of their drug portfolio.
- Risk Assessment: The patent landscape, including litigation history and potential validity challenges, directly impacts the risk profile of investing in companies involved with drugs synthesized via this method.
Key Takeaways
United States Patent 7,807,135 claims a specific method for synthesizing N-aryl substituted piperidine derivatives. The patent's scope is defined by its claims covering reactants, catalysts, bases, and reaction conditions. Assigned to Merck & Co., Inc., its expiration around October 2020 has opened the door for generic competition, assuming no other relevant patents remain in force. The patent landscape is characterized by the potential for infringement litigation and is influenced by a broader portfolio of related patents covering composition, formulation, and use. Understanding this patent and its context is crucial for R&D planning and investment decisions in the pharmaceutical sector, particularly for antipsychotic medications.
Frequently Asked Questions
What is the primary application of compounds synthesized using the method in US 7,807,135?
The N-aryl substituted piperidine derivatives synthesized using the method claimed in US 7,807,135 are primarily used as active pharmaceutical ingredients (APIs) in antipsychotic medications. These drugs target neurological and psychiatric conditions by modulating neurotransmitter activity in the brain.
How does US 7,807,135 differ from a patent on the drug itself (composition of matter)?
A patent on the drug itself (composition of matter) protects the novel chemical compound that forms the active ingredient. US 7,807,135, conversely, protects a specific method or process for making that compound. The composition of matter patent generally provides broader and longer-lasting exclusivity.
What is meant by "freedom to operate" in the context of this patent?
Freedom to operate (FTO) means that a company can manufacture, use, or sell a product or process without infringing the intellectual property rights of others. For US 7,807,135, FTO would have been limited for generic manufacturers while the patent was active. Post-expiration, FTO regarding this specific synthesis method is generally established.
Are there alternative synthesis methods to the one claimed in US 7,807,135?
Yes, chemical synthesis is an area of active research, and multiple pathways can often be developed to produce the same compound. The existence of US 7,807,135 incentivizes research into alternative, non-infringing, or more efficient synthesis methods.
What is an "Inter Partes Review" (IPR) and how could it affect this patent?
An Inter Partes Review (IPR) is a trial proceeding conducted at the U.S. Patent and Trademark Office (USPTO) to review the patentability of one or more claims in a patent. Third parties can file an IPR petition arguing that the patent claims are invalid based on prior art. If successful, an IPR can result in the invalidation or narrowing of patent claims, impacting its enforceability and market exclusivity.
Citations
[1] Merck & Co., Inc. (2010). Method of preparing N-aryl substituted piperidine derivatives. U.S. Patent 7,807,135. Washington, D.C.: U.S. Patent and Trademark Office.
